Limitations, agreements, and source contact

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) · Source last updated 2026-02-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

Sara_Tolaney@dfci.harvard.edu

organization

Dana-Farber Cancer Institute

phone

(877) 442-3324

title

Sara Tolaney, MD, MPH

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice